Individuals with Down syndrome (DS) have an increased risk of numerous co-occurring
conditions, including the neuropsychiatric condition known as Down Syndrome Regression
Disorder (DSRD). A DSRD diagnosis often includes a sub-acute onset of catatonia, mutism,
depersonalization, loss of ability to perform activities of daily living, hallucinations,
delusions, and aggression and is most commonly observed in adolescents and young adults.
The study evaluates the safety and efficacy of three currently prescribed therapies:
lorazepam, intravenous immunoglobulin (IVIG) and tofacitinib.